A condition called fetal and neonatal alloimmune thrombocytopenia (FNAIT) can be deadly in newborns. That’s why Johnson & Johnson is passionate about developing a treatment for the disorder.

For Myasthenia Gravis Awareness Month, discover more about the disease, learn how one woman lives with this rare autoantibody condition and why Johnson & Johnson is working to find new treatments for patients like her.

It’s estimated that over 300 million people around the globe are living with a rare disease.

Hetal Patel, an immunodermatology medical director at Johnson & Johnson, forged her own career path—and now she’s living into her passion for advocacy, education and innovation.

Imagine reversing the course of conditions like Alzheimer’s or multiple sclerosis, in which cells of the central nervous system stop working or die. Researchers at Johnson & Johnson are hot on the trail of innovative solutions that may do just that, preventing often-debilitating symptoms along the way.

Imagine having a disease that many doctors have never seen before. That’s what Marty Verel experienced when he was told he had AL amyloidosis—and it’s what hematologist Brendan Weiss, M.D., is determined to help change. For Rare Disease Day, Dr. Weiss shares what he’s learned studying the rare disease.

Meet two men who have the rare immune system disorder: a doctor who created a groundbreaking registry for it—and a patient who signed up for it.